- Home
- OTLK vs KINS Comparison
OTLK vs KINS Comparison
Compare OTLK & KINS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | OTLK | KINS |
|---|---|---|
| Founded | 2010 | 1886 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Property-Casualty Insurers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 249.6M | 279.5M |
| IPO Year | 2016 | 2013 |
Fundamental Metrics
Financial Performance| Metric | OTLK | KINS |
|---|---|---|
| Price | $0.52 | $19.95 |
| Analyst Decision | Buy | |
| Analyst Count | 4 | 0 |
| Target Price | ★ $5.03 | N/A |
| AVG Volume (30 Days) | ★ 3.8M | 57.7K |
| Earning Date | 08-14-2026 | 11-05-2026 |
| Dividend Yield | N/A | ★ 1.19% |
| EPS Growth | 55.91 | ★ 94.59 |
| EPS | N/A | ★ 0.66 |
| Revenue | $8,146,123.00 | ★ $214,867,301.00 |
| Revenue This Year | N/A | $18.83 |
| Revenue Next Year | $6,355.64 | $15.85 |
| P/E Ratio | ★ N/A | $30.56 |
| Revenue Growth | N/A | ★ 38.50 |
| 52 Week Low | $0.16 | $13.83 |
| 52 Week High | $2.54 | $20.90 |
Technical Indicators
Market Signals| Indicator | OTLK | KINS |
|---|---|---|
| Relative Strength Index (RSI) | 40.37 | 62.25 |
| Support Level | $0.40 | $18.52 |
| Resistance Level | $0.72 | $20.52 |
| Average True Range (ATR) | 0.05 | 0.48 |
| MACD | 0.01 | 0.21 |
| Stochastic Oscillator | 50.19 | 87.06 |
Price Performance
Historical ComparisonAbout OTLK Outlook Therapeutics Inc.
Outlook Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing ONS-5010, a monoclonal antibody, or mAb, for various ophthalmic indications. The Company have received marketing authorization for an ophthalmic formulation of ONS-5010/LYTENAVA (bevacizumab-gamma) for use in treating wet age-related macular degeneration, or wet AMD, in the European Union, and United Kingdom. The product pipeline includes ONS-5010/LYTENAVA, which is in total eight NORSES; ONS-5010 Clinical Progress, Unmet Patient Needs, New Ophthalmic Anti-VEGF, and Potential First Line Therapy.
About KINS Kingstone Companies Inc.
Kingstone Companies Inc offers property and casualty insurance products through its subsidiary engaged in writing business through retail and wholesale agents and brokers. Its products include Personal lines, Livery physical damage, and Others. It operates in single segment, property and casualty insurance. It derives substantially all of its revenue from KICO, including revenues from earned premiums, ceding commissions from quota share reinsurance, net investment income generated from its investment portfolio, and net realized gains and losses on investment securities.